PharmaCyte Biotech Inc. - news published 76 - readings 970

BACK
PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc.

Quarterly Report for Quarter Ending January 31, 2025 (Form 10-Q)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ t ...

Continue reading
17.03.2025
PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc.

Quarterly Report for Quarter Ending October 31, 2024 (Form 10-Q)

PHARMACYTE BIOTECH, INC. Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...

Continue reading
13.12.2024
PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc.

Initial Registration Statement for Employee Benefit Plan (Form S-8)

As filed with the Securities and Exchange Commission on December 4, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 62-1772151 (State or other jurisdiction of incorporation or ...

Continue reading
04.12.2024
PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc.

Annual Report for Fiscal Year Ending April 30, 2024 (Form 10-K)

PHARMACYTE BIOTECH, INC. Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30 , 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For th ...

Continue reading
13.08.2024
PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc.

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease - Form 8-K

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" ...

Continue reading
23.05.2024